Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 34 points (-0.2%) at 15,991 as of Tuesday, Dec. 10, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,637 declining with 176 unchanged. The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.2%. A company within the industry that fell today was Sanofi ( SNY), up 1.1%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Incyte ( INCY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Incyte is up $1.84 (4.0%) to $47.99 on light volume. Thus far, 610,919 shares of Incyte exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $45.77-$48.40 after having opened the day at $46.35 as compared to the previous trading day's close of $46.15. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $7.5 billion and is part of the health care sector. Shares are up 177.8% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk. Get the full Incyte Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.